ERBB2 and metastatic malignant neoplasm in the lymph nodes: In addition, we revealed more frequent overexpression of HER2 in patients with lymph node metastasis than in those without lymph node metastasis (23.44% vs. 12.50%)—the observation which has been confirmed by other authors [60]; nevertheless, in our study, this relation did not reach a statistical significance.